

REMARKS

The present application has been subject to a restriction requirement under 35 U.S.C. §§121 and 372 as follows:

Group I, claims 1 and 4-20, drawn to methods for treatment of neurodegenerative disorders;

Group II, claims 3 and 21-26, drawn to pharmaceutical compositions.

As indicated *supra*, Applicants elect without traverse, Group 1, claims 4-20, drawn to methods for treatment of neurodegenerative disorders.

In addition, the Examiner has imposed an election of species requirement on the claims in this application. Specifically, Applicants have also been required to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable and to identify the claims readable on the elected species, including any claims subsequently added. The species have been identified as different pathological conditions and disorders specifically recited in claims 4-5, 8-10, 15 and 17, and different pharmaceutical compounds and compositions specifically recited in claims 18, 22 and 24-26.

In response, Applicants elect (i) Alzheimer's disease and dementia as a pathological condition/disorder and (ii) vildagliptin as the DPP-IV inhibitor.

Finally, it is submitted that claims 1, 4-12, 17-20 encompass the elected invention.

Respectfully submitted,



Ann R. Pokalsky
Registration No.: 34,697
Attorney for Applicants

DILWORTH & BARRESE, LLP
1000 Woodbury Road, Suite 405
Woodbury, New York 11797
Tel. No. (516) 228-8484
Fax No. (516) 228-8516